Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
Clinical Trials are divided into the following categories:
Enhancing treatment outcomes after after gynaecological cancer through exercise
Trial Status:
Not yet recruiting
|
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study Evaluating Efficacy, Safety and Tolerability of BI 1291583 qd Over at Least 24 Weeks in Patients with Bronchiectasis (Airleaf™)
A trial studying the safety & effectiveness of a new injection therapy for the treatment of ulcerative colitis.
A multicentre study of the safety and effectiveness of CC-93538 in adolescent and adult participants with Eosinophilic Esophagitis
Trial Status:
Active, not recruiting
|
A trial studying the safety & effectiveness of a new enema therapy for the treatment of left-sided Ulcerative Colitis
A study of the safety and effectiveness of tezepelumab in adolescent and adult participants with Eosinophilic Esophagitis
Duloxetine versus pregabalin to treat opioid-resistant nerve pain in cancer patients
Testing the safety and effectiveness of Fenofibrate in reducing diabetic retinopathy in adults with Type 1 diabetes
Evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases.
A study to find out whether BI 1015550 improves lung function in people with Idiopathic Pulmonary Fibrosis.